Welcome to Competition Currents, a monthly newsletter for Greenberg Traurig clients and colleagues highlighting significant recent developments in global antitrust and competition law.
StockNews.com started coverage on shares of Intersect ENT (NASDAQ:XENT – Get Rating) in a note issued to investors on Friday. The firm set a “sell” rating on the medical equipment provider’s stock. Intersect ENT stock opened at $28.24 on Friday. The stock has a 50-day moving average of $28.03 and a two-hundred day moving average […]
Federal Trade Commission (FTC), Department of Justice (DOJ), U.S. Litigation, Dutch ACM decisions, policies, and market studies, Dutch Courts, UK State of Competition, Antitrust enforcement, Antitrust litigation, Mergers
Intersect ENT (NASDAQ:XENT – Get Rating) and LMF Acquisition Opportunities (NASDAQ:LMAO – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings. Profitability This table compares Intersect ENT and LMF […]
StockNews.com started coverage on shares of Intersect ENT (NASDAQ:XENT – Get Rating) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the medical equipment provider’s stock. Shares of NASDAQ:XENT opened at $28.24 on Thursday. The firm’s 50 day moving average is $27.99 and its two-hundred day moving average is […]